news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
List view / Grid view
Neurosciences
news
Preventing F-actin build-up improves drosophila healthspan
Disrupting F-actin in aged brains restored brain autophagy to youthful levels and reversed some cellular markers of brain ageing.
whitepaper
Beyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
news
Specific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
news
Mechanism that controls reactivation of neural stem cells discovered
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
news
Promising development of new drug to treat Alzheimer’s disease
In lab and fruit fly studies, the new peptide inhibitor effectively acted on both major aggregation-promoting hotspots of Tau proteins.
news
New link found between immune system and neurological disease
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
news
New humanised neuroinflammation in vitro platform
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
Brain organoids: investigating the progression of Huntington’s disease
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
article
Women in STEM with Kristina Torfgard
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.
news
New pathway to transition neural stem cells into a proliferative state
Understanding the signalling pathway controlling neural stem cell reactivation could offer a strategy for using existing drugs to treat neurodevelopmental disorders.
news
Revolutionary blood test identifies patients with brain injuries
Orlando Health Orlando Regional Medical Center is the first hospital in the world to use the blood test.
webinar
Unprecedented fragment-based screening using Spectral Shift for GPCRs
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.